Terms: = Lung cancer AND FAS, FAS1, 355, ENSG00000026103, FASTM, APO-1, P25445, CD95, ALPS1A, TNFRSF6, APT1 AND Treatment
334 results:
1. Application of 18F-FDG PET/CT imaging radiomics in the differential diagnosis of single-nodule pulmonary metastases and second primary lung cancer in patients with colorectal cancer.
Yu Y; Zhu J; Sang S; Yang Y; Zhang B; Deng S
J Cancer Res Ther; 2024 Apr; 20(2):599-607. PubMed ID: 38687930
[TBL] [Abstract] [Full Text] [Related]
2. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
3. Knowledge, attitude, and practice of lung cancer screening and associated factors among high-risk population in Lanzhou, China: A cross-sectional study.
Zhang T; Mao Z; Li W; Ma M; Li G; Qiao X; Wang H
Medicine (Baltimore); 2024 Mar; 103(9):e37431. PubMed ID: 38428855
[TBL] [Abstract] [Full Text] [Related]
4. Quality control of postoperative radiotherapy for non-small cell lung cancer: A study of mediastinal shift.
Zhang W; Zhang Y; Ouyang WW; Fa Su S; Ma Z; Li QS; Gang Yang W; Xia Chen X; Liu J; Lu B
Cancer Radiother; 2024 Apr; 28(2):152-158. PubMed ID: 38320903
[TBL] [Abstract] [Full Text] [Related]
5. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in cancer.
Tanabe S; Boonstra E; Hong T; Quader S; Ono R; Cabral H; Aoyagi K; Yokozaki H; Perkins EJ; Sasaki H
Genes (Basel); 2023 Nov; 14(11):. PubMed ID: 38003016
[TBL] [Abstract] [Full Text] [Related]
7. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell lung cancer.
Rudin CM; Liu SV; Soo RA; Lu S; Hong MH; Lee JS; Bryl M; Dumoulin DW; Rittmeyer A; Chiu CH; Ozyilkan O; Johnson M; Navarro A; Novello S; Ozawa Y; Tam SH; Patil NS; Wen X; Huang M; Hoang T; Meng R; Reck M
J Clin Oncol; 2024 Jan; 42(3):324-335. PubMed ID: 37976444
[TBL] [Abstract] [Full Text] [Related]
8. Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway.
Liu B; Zheng X; Li J; Yao P; Guo P; Liu W; Zhao G
BMC Cancer; 2023 Nov; 23(1):1070. PubMed ID: 37932661
[TBL] [Abstract] [Full Text] [Related]
9. Inflammation index predicts radiation-induced lung injury and prognosis in lung tumors treated with stereotactic body radiation therapy.
Shan J; Xie X; Gu B; Sun X; Liu H
Jpn J Radiol; 2024 Jan; 42(1):102-108. PubMed ID: 37684513
[TBL] [Abstract] [Full Text] [Related]
10. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Özgüroğlu M; Kilickap S; Sezer A; Gümüş M; Bondarenko I; Gogishvili M; Nechaeva M; Schenker M; Cicin I; Ho GF; Kulyaba Y; Zyuhal K; Scheusan RI; Garassino MC; He X; Kaul M; Okoye E; Li Y; Li S; Pouliot JF; Seebach F; Lowy I; Gullo G; Rietschel P
Lancet Oncol; 2023 Sep; 24(9):989-1001. PubMed ID: 37591293
[TBL] [Abstract] [Full Text] [Related]
11. BCKDK regulates breast cancer cell adhesion and tumor metastasis by inhibiting TRIM21 ubiquitinate talin1.
Xu C; Yang K; Xuan Z; Li J; Liu Y; Zhao Y; Zheng Z; Bai Y; Shi Z; Shao C; Zhang L; Sun H
Cell Death Dis; 2023 Jul; 14(7):445. PubMed ID: 37460470
[TBL] [Abstract] [Full Text] [Related]
12. A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer.
Zhang Y; Zhang L; Cao S; Wang Y; Ling X; Zhou Y; Zhong H
Cancer Med; 2023 Aug; 12(15):15998-16010. PubMed ID: 37409360
[TBL] [Abstract] [Full Text] [Related]
13. Genomic characterisation of de novo EGFR copy number gain and its impact on the efficacy of first-line EGFR-tyrosine kinase inhibitors for EGFR mutated non-small cell lung cancer.
Xu Y; Yan J; Zhou C; Wu L; Wang H; Zhao J; Zhou M; Wang J; Zheng X; Zhang L; Jiang K; Zheng X; Miao Q; Wu S; Zou Z; Lian R; He Y; Chen R; Yang S; Li Y; Chen S; Lin G
Eur J Cancer; 2023 Jul; 188():81-89. PubMed ID: 37201385
[TBL] [Abstract] [Full Text] [Related]
14. Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis.
Rim CH; Cho WK; Park S; Yoon WS; Yang DS
Int J Surg; 2023 Apr; 109(4):1006-1014. PubMed ID: 36974686
[TBL] [Abstract] [Full Text] [Related]
15. The molecular mechanisms of apoptosis accompanied with the epigenetic regulation of the NY-ESO-1 antigen in non-small lung cancer cells treated with decitabine (5-aza-CdR).
Inchakalody VP; Hydrose SP; Krishnankutty R; Merhi M; Therachiyil L; Sasidharan Nair V; Elashi AA; Khan AQ; Taleb S; Raza A; Yoosuf ZSKM; Fernandes Q; Al-Zaidan L; Mestiri S; Taib N; Bedhiafi T; Moustafa D; Assami L; Maalej KM; Elkord E; Uddin S; Al Homsi U; Dermime S
Eur J Pharmacol; 2023 Apr; 945():175612. PubMed ID: 36822455
[TBL] [Abstract] [Full Text] [Related]
16. Bigelovin inhibits hepatocellular carcinoma cell growth and metastasis by regulating the MAPT-mediated fas/fasL pathway.
Wang B; Nie CH; Xu J; Wan DL; Xu X; He JJ
Neoplasma; 2023 Apr; 70(2):208-215. PubMed ID: 36812233
[TBL] [Abstract] [Full Text] [Related]
17. Afatinib in Untreated Stage IIIB/IV lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC
Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452
[TBL] [Abstract] [Full Text] [Related]
18. Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer.
Zhang J; Xu K; Yang F; Qiu Y; Li J; Li J; Wang W; Tan G; Zou Z; Kang F
Eur J Med Chem; 2023 Mar; 250():115192. PubMed ID: 36801517
[TBL] [Abstract] [Full Text] [Related]
19. The Oral PI3Kδ Inhibitor Linperlisib for the treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial.
Wang T; Sun X; Qiu L; Su H; Cao J; Li Z; Song Y; Zhang L; Li D; Wu H; Zhang W; Li J; Zhou K; Zhou H; Yang Y; Li Z; Cen H; Cai Z; Zhang Z; Fu W; Jin J; Li F; Wu W; Gu X; Zhu W; Liu L; Li Z; Yi S; Bao H; Xu Z; Qiu L
Clin Cancer Res; 2023 Apr; 29(8):1440-1449. PubMed ID: 36735519
[TBL] [Abstract] [Full Text] [Related]
20. Interleukin 8 in plasma is an efficacy marker for advanced non-small cell lung cancer treated with hypofractionated radiotherapy and PD-1 blockade.
Kang P; Liu D; Li L; Guo X; Ye Y; Li Y; Jiang Q; Lin S; Yuan Q
Cytokine; 2023 Mar; 163():156133. PubMed ID: 36724715
[TBL] [Abstract] [Full Text] [Related]
[Next]
